Halozyme Therapeutics (NASDAQ:HALO) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Halozyme Therapeutics (NASDAQ:HALO) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02, Zacks reports. Halozyme Therapeutics had a return on equity of 179.82% and a net margin of 41.43%.

Halozyme Therapeutics Stock Performance

HALO stock opened at $57.90 on Wednesday. Halozyme Therapeutics has a 1-year low of $35.50 and a 1-year high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The firm has a market cap of $7.37 billion, a PE ratio of 19.17, a P/E/G ratio of 0.44 and a beta of 1.25. The business’s 50-day moving average price is $52.69 and its two-hundred day moving average price is $54.51.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. JMP Securities lifted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company lowered their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, February 4th. Finally, Piper Sandler upped their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $60.89.

Insiders Place Their Bets

In other news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares of the company’s stock, valued at $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.